Understanding Regulatory RNA in High Blood Pressure and Kidney Damage
Regulatory RNA in Hypertension and Renal Injury
['FUNDING_R01'] · UNIVERSITY OF ARIZONA · NIH-11223199
This project looks at how tiny genetic regulators called microRNAs affect high blood pressure and kidney damage, especially in African American patients.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF ARIZONA (nih funded) |
| Locations | 1 site (TUCSON, UNITED STATES) |
| Trial ID | NIH-11223199 on ClinicalTrials.gov |
What this research studies
High blood pressure is a major health concern worldwide, often leading to kidney damage in some individuals. This work explores how small genetic molecules, called microRNAs, play a role in the development of high blood pressure and related kidney problems. Researchers are particularly interested in how these microRNAs might contribute to kidney damage, especially in groups like African American patients who often experience more severe symptoms. By understanding these tiny regulators, we hope to find new ways to protect the kidneys from the effects of high blood pressure.
Who could benefit from this research
Good fit: Patients with high blood pressure, especially those experiencing kidney damage or who are of African American descent, might benefit from future treatments developed from this research.
Not a fit: Patients without high blood pressure or kidney damage are unlikely to directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to new ways to prevent or treat high blood pressure and kidney damage, particularly for those at higher risk.
How similar studies have performed: Other studies have shown that microRNAs are important regulators in cardiovascular and kidney health, suggesting this approach builds on existing knowledge.
Where this research is happening
TUCSON, UNITED STATES
- UNIVERSITY OF ARIZONA — TUCSON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LIANG, MINGYU — UNIVERSITY OF ARIZONA
- Study coordinator: LIANG, MINGYU
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.